tiprankstipranks
Calidi Biotherapeutics Secures Investment, Expands Advisory Board
Company Announcements

Calidi Biotherapeutics Secures Investment, Expands Advisory Board

Pick the best stocks and maximize your portfolio:

Calidi Biotherapeutics (CLDI) has issued an update.

Calidi Biotherapeutics, Inc. has entered into a Subscription Agreement with accredited investor Dr. Ronald Rigor, selling nearly 699,000 shares and warrants to purchase an additional 600,000 shares, culminating in a $1 million private placement. Dr. Rigor’s investment in subsidiary Nova Cell has also led to him receiving 25% of Nova Cell’s shares and the assignment of certain intellectual property rights. Acknowledging his contributions, Dr. Rigor has been appointed to Calidi’s Scientific and Medical Advisory Board and granted 5,000 stock options. These strategic moves aim to bolster the company’s advancements, leveraging Dr. Rigor’s stem cell expertise.

For a thorough assessment of CLDI stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyCalidi files to sell 6.94M shares of common stock for holders
TipRanks Auto-Generated NewsdeskCalidi Biotherapeutics Reveals Promising Virotherapy Data
TheFlyCalidi presents data on RTNova systemic technology in metastatic lung cancer
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App